Preoperative Resting Heart Rate and 30-Day Heart Failure After Off-Pump Coronary Artery Bypass Grafting.

Ann Thorac SurgJun 9, 2026 (epub)
Clinical ResearchCardiologyCardiothoracic Surgery

Zhao Zhang, Wenqian Zhai, Hong Xu et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial analyzed the relationship between preoperative resting heart rate (RHR) and 30-day heart failure in adults aged 60 and older undergoing off-pump coronary artery bypass grafting. Among 1952 patients, 69 (3.5%) developed heart failure. Higher RHR was associated with increased risk, with an adjusted odds ratio of 1.47 per 10 beats/min.

Key findings

  • 3.5% of patients experienced 30-day heart failure post-surgery.
  • Higher preoperative RHR was linked to heart failure, with an adjusted odds ratio of 1.47 per 10 beats/min.
  • Risk of heart failure increased steeply beyond a preoperative RHR of 80 beats/min.
  • Intraoperative heart rate metrics showed stronger indirect associations with heart failure than hypotension metrics.

Why it matters

Understanding the association between preoperative RHR and postoperative heart failure can help clinicians identify at-risk patients and potentially guide preoperative assessments and management strategies.

Source

PubMed · PMID 42264018

Published in Ann Thorac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.